434 related articles for article (PubMed ID: 8547213)
1. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
Negrescu EV; Grünberg B; Kratzer MA; Lorenz R; Siess W
Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
3. Synergistic phosphorylation of platelet rap1B by SIN-1 and iloprost.
Grünberg B; Negrescu E; Siess W
Eur J Pharmacol; 1995 Feb; 288(3):329-33. PubMed ID: 7539769
[TBL] [Abstract][Full Text] [Related]
4. In vitro inhibition of human and rat platelets by NO donors, nitrosoglutathione, sodium nitroprusside and SIN-1, through activation of cGMP-independent pathways.
Priora R; Margaritis A; Frosali S; Coppo L; Summa D; Di Giuseppe D; Aldinucci C; Pessina G; Di Stefano A; Di Simplicio P
Pharmacol Res; 2011 Sep; 64(3):289-97. PubMed ID: 21539916
[TBL] [Abstract][Full Text] [Related]
5. Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo.
Spiecker M; Darius H; Meyer J
Thromb Res; 1993 Jun; 70(5):405-15. PubMed ID: 7690993
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
7. Platelet rap1B phosphorylation is a sensitive marker for the action of cyclic AMP- and cyclic GMP-increasing platelet inhibitors and vasodilators.
Grünberg B; Kruse HJ; Negrescu EV; Siess W
J Cardiovasc Pharmacol; 1995 Apr; 25(4):545-51. PubMed ID: 7596121
[TBL] [Abstract][Full Text] [Related]
8. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin.
Russo I; Traversa M; Bonomo K; De Salve A; Mattiello L; Del Mese P; Doronzo G; Cavalot F; Trovati M; Anfossi G
Obesity (Silver Spring); 2010 Apr; 18(4):788-97. PubMed ID: 19834474
[TBL] [Abstract][Full Text] [Related]
9. Studies on inhibition of human platelet function by sodium nitroprusside. Kinetic evaluation of the effect on aggregation and cyclic nucleotide content.
Anfossi G; Russo I; Massucco P; Mattiello L; Balbo A; Cavalot F; Trovati M
Thromb Res; 2001 May; 102(4):319-30. PubMed ID: 11369425
[TBL] [Abstract][Full Text] [Related]
10. Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost.
Anfossi G; Massucco P; Mularoni E; Cavalot F; Mattiello L; Trovati M
Prostaglandins Leukot Essent Fatty Acids; 1993 Nov; 49(5):839-45. PubMed ID: 7508131
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide stimulates the phosphorylation of rap1b in human platelets and acts synergistically with iloprost.
Reep BR; Lapetina EG
Biochem Biophys Res Commun; 1996 Feb; 219(1):1-5. PubMed ID: 8619788
[TBL] [Abstract][Full Text] [Related]
12. Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation.
Lidbury PS; Antunes E; de Nucci G; Vane JR
Br J Pharmacol; 1989 Dec; 98(4):1275-80. PubMed ID: 2482103
[TBL] [Abstract][Full Text] [Related]
13. Adenosine diphosphate-induced aggregation is enhanced in platelets obtained from patients with thrombotic primary antiphospholipid syndrome (t-PAPS): Role of P2Y
Leonardi GR; Lescano CH; Costa JL; Mazetto B; Orsi FA; Monica FZ
J Thromb Haemost; 2022 Jul; 20(7):1699-1711. PubMed ID: 35395698
[TBL] [Abstract][Full Text] [Related]
14. Interaction between SIN-1 and prostacyclin in inhibiting platelet aggregation.
Bult H; Fret HR; Herman AG
J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S120-3. PubMed ID: 2484689
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of human platelet aggregation and thromboxane A2 formation by L-arginine in vivo and in vitro.
Bode-Böger SM; Böger RH; Galland A; Frölich JC
Naunyn Schmiedebergs Arch Pharmacol; 1998 Feb; 357(2):143-50. PubMed ID: 9521487
[TBL] [Abstract][Full Text] [Related]
16. Synergistic platelet inhibitory effect of the phosphodiesterase inhibitor piroximone and iloprost.
Buerke M; Dieterich HA; Meyer J; Darius H
Agents Actions Suppl; 1992; 37():71-7. PubMed ID: 1378692
[TBL] [Abstract][Full Text] [Related]
17. MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation.
Guarino ML; Massimi I; Alemanno L; Conti L; Angiolillo DJ; Pulcinelli FM
J Thromb Thrombolysis; 2021 Apr; 51(3):625-632. PubMed ID: 32803738
[TBL] [Abstract][Full Text] [Related]
18. Potential interactions between iloprost and SIN-1 on platelet aggregation and myocardial infarct size in vivo.
Aitchison KA; Coker SJ
Eur J Pharmacol; 1999 Jun; 374(1):59-69. PubMed ID: 10422641
[TBL] [Abstract][Full Text] [Related]
19. Roles for both cyclic GMP and cyclic AMP in the inhibition of collagen-induced platelet aggregation by nitroprusside.
Jang EK; Azzam JE; Dickinson NT; Davidson MM; Haslam RJ
Br J Haematol; 2002 Jun; 117(3):664-75. PubMed ID: 12028040
[TBL] [Abstract][Full Text] [Related]
20. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
